MeCure Industries PLC
MeCure Industries PLC develops and commercializes pharmaceutical products, generating revenue primarily through the sale of prescription and over-the-counter medications.
Business. MeCure Industries PLC (MECURE.LG) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MeCure Industries PLC (MECURE.LG) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
MeCure Industries PLC has a debt-to-equity ratio of 2.79, indicating a capital structure that is heavily leveraged, with long-term debt accounting for a significant portion of its total liabilities. The company's liquidity position is assessed as medium, with a current ratio of 1.26 and negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints.
In terms of profitability, the company's return on equity (ROE) of 32.6% is strong, outperforming the typical pharmaceutical industry benchmark of 15-20%. However, its return on assets (ROA) of 7.89% is in line with the industry median, indicating efficient use of assets but not exceptional performance.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks, particularly in the Nigerian market where the company is headquartered.
Looking ahead, the company's growth trajectory is uncertain. While it has a free cash flow of 1.497 billion NGN, capital expenditures of -10.053 billion NGN suggest significant reinvestment in operations. Analysts have issued a single "Hold" recommendation, with no strong buy or buy ratings, indicating a neutral outlook on the company's near-term prospects.
The company's risk profile includes medium liquidity risk and low dilution potential, with no recent signs of equity issuance or share buybacks. However, the negative operating cash flow of -2.43 billion NGN raises concerns about its ability to fund operations without external financing.
Recent filings and transcripts have not revealed any material events or strategic shifts. The company's financial performance appears stable, but its reliance on debt financing and lack of geographic diversification remain key risks to its long-term sustainability.
- MeCure Industries PLC has a strong ROE of 32.6%, but its ROA of 7.89% is in line with industry norms.
- The company's capital structure is highly leveraged, with a debt-to-equity ratio of 2.79.
- Free cash flow is positive, but capital expenditures are substantial, indicating ongoing investment in operations.
- Analysts have issued a single "Hold" recommendation, with no strong buy or buy ratings.
- The company's liquidity position is medium, with a current ratio of 1.26 and negative net cash after subtracting total debt.
- Revenue is concentrated in a single business segment, with no disclosed geographic diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MeCure Industries PLC Market data — financials · 2026-05-28
- MeCure Industries PLC Market data — analyst estimates · 2026-05-28